Spyre Therapeutics (SYRE) Stifel Virtual Immunology and Inflammation Forum summary

Strategic focus and clinical development

• Targeting unmet needs in autoimmune diseases with two ongoing phase II trials in IBD and rheumatic diseases.

• Utilizing co-formulated combinations of optimized antibodies against α4β7, TL1A, and IL-23 p19 to address multiple disease pathways.

• Announced first dosing of anti-TL1A antibody in three rheumatic diseases, aiming for quarterly or twice-annual dosing.

• Expecting nine proof-of-concept placebo-controlled readouts over the next two years, covering indications with over $60 billion in annual revenue.

• Platform and basket studies designed to deliver indication-leading profiles and substantial returns for stakeholders.

Rationale for combination therapies and competitive landscape

• Combination therapies in IBD are seen as the most probable way to break the efficacy ceiling, supported by studies like J&J's VEGA and AFFINITY.

• VEGA showed nearly double the remission rate with combination therapy versus monotherapy in ulcerative colitis.

• Duet studies are expected to provide further insight into efficacy and safety in refractory populations.

• Co-formulation of antibodies chosen over bispecifics due to lower immunogenicity risk, better target engagement, and flexible dosing ratios.

• Small molecule orals are unlikely to match the efficacy of biologics or optimized antibody combinations.

Clinical trial design and upcoming milestones

• SKYLINE platform study investigates three monotherapies and their combinations, with open-label Part A and placebo-controlled Part B.

• Part A aims for early proof of concept, with readouts expected in 2026; Part B will evaluate optimal products for phase III.

• Subcutaneous and IV induction strategies tailored to each antibody's pharmacology, with IV loading for higher efficacy where needed.

• Open-label data will focus on objective disease improvement measures, with benchmarks from previous studies.

• Six readouts expected next year from both IBD and rheumatic disease studies, with additional industry readouts anticipated.